• Blog
  • Carglumic Acid Market Report

    Carglumic Acid Market Report

    Carglumic Acid Market Report
    Report code - SR1710 Delivery - 2 Weeks
    Carglumic Acid Market Size, Share, Trend, Forecast, & Industry Analysis: 2021-2026
    See more...

    Market Insights

    What is Carglumic Acid?

    Carglumic acid is stated as an orphan drug that's mainly wont to treat hyperammonemia, also called NAGS Syndrome, a rare genetic defect that happens mainly thanks to lack of an enzyme called N-acetyl glutamate synthase (NAGS) within the liver. This results in increased levels of ammonia within the blood. Several neurological disorders like hepatic encephalopathy, congenital deficiencies of urea cycle enzymes, and Reye’s syndrome, among other metabolic disorders arise with the high levels of ammonia demanding the requirement for carglumic acid.

    The Carglumic Acid Market is estimated to grow from USD 122.3 million in 2020 to USD 188.8 million by 2026 at a healthy CAGR of 7.7% during the forecast period.

    Carglumic Acid Market- Research Scope

    Base Year of Study

    2020

    Trend Period

    2015-2019

    Forecast Period

    2021-2026

    Market Size in 2020

    US$ 122.3 million

    Market Size in 2026

    US$ 188.8 million

    Market Growth (2021-2026)

    7.7% CAGR

     

    Figure: Carglumic Acid Market Size, 2020-2026 (USD Million)

    Carglumic-Acid-Market-Forecast

    Wish to get a free sample? Register Here

    Market Drivers

    Carglumic acid has significantly gained popularity as it is used to treat urea cycle disorders, thus, augmenting the market growth. The deficiency of two transporters or any one of the hepatic enzymes that are engaged in the detoxification of ammonia causes urea cycle disorders. This further results in severe brain injury, which can only be prevented by reducing the build-up of ammonia, the most toxic metabolite. Carglumic acid has thus been increasingly used for the treatment of multiple disorders such as treating patients with hyperammonemia, preventing ammonia intoxication, preventing brain damage, accelerating cancer cell suppression & promoting apoptosis.

    Covid-19 Impact Analysis

    The outbreak of COVID-19 significantly impacted the carglumic acid industry as the pandemic adversely affected the international trade activities, supply chains, and manufacturing activities across the globe. Moreover, the production of carglumic acid reduced amidst the COVID-19 pandemic as the industry players had to temporarily shut down production facilities or operate the facilities below the optimal production capacities to prevent the spread of coronavirus infection.

    Segments' Analysis

    Distribution Channel Trends

    Based on distribution channels, the carglumic acid market has been divided into hospital pharmacies, retail pharmacies, and e-commerce channels. The hospital pharmacies segment held a substantial market share of more than 50% in 2020. This is mainly attributed to well-established hospital infrastructure, easy availability of medicines, up-to-date stocking of medicines, offers patients’ ease, preference for the purchase of drugs, and easy reliability of pharmacy stores.

    Regional Trends

    By region, the North American Carglumic Acid market accounted for the largest share of almost 40% in 2020 and is expected to grow at a significant CAGR during the review period. The carglumic acid market growth can be ascribed to strong healthcare expenditure, the presence of highly qualified healthcare professionals, and a significant rise in ammonia levels in patients leading to extensive muscle contractions.

    The Asia-Pacific Carglumic Acid market is expected to grow at the highest CAGR during the review on account of the growth of the major end-use industries. China is the key contributor owing to the presence of a large population which adds to the prevalence of rare diseases. Moreover, improving medical infrastructure in the developing countries as well as favorable government support further bolsters the regional market growth in the coming years.

    Critical Questions Answered in the Report

    This market research report provides in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global carglumic acid market. The historic years considered for the study are 2016-2019, the base year is 2020, the estimated year is 2021, and the forecast period is 2022-2026. Following are the critical questions answered in the report.

    • What are the key trends in the carglumic acid market?
    • How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in the next five years?
    • What is the impact of COVID-19 on carglumic acid market?
    • What are the key strategies adopted by the major vendors to lead in the carglumic acid market?
    • What is the market share of the top vendors?

    Get the full scope of the report. Register Here

    Key Players

    Key players operating in the Carglumic Acid Market are-

    • Apothecon Pharmaceuticals Pvt Ltd (India)
    • Manus Aktteva Biopharma LLP (India)
    • Recordati Rare Diseases Inc (US)
    • Dipharma Francis S r l (Italy)
    • Civentichem LLC (US)
    • Dipharma S A (Switzerland)
    • NURAY CHEMICALS (India)
    • NOVITIUM PHARMA LLC (US)
    • Suven Life Sciences Limited (India)
    • Biophore India Pharmaceuticals Pvt Ltd (India)

    Target Audience

    The target audience of Carglumic Acid Market includes-

    • Carglumic Acid Vendors
    • Carglumic Acid Manufacturers
    • Carglumic Acid Distributors
    • Organizations
    • Government Bodies.

    Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at sales@stratviewresearch.com.

    Frequently Asked Questions (FAQs)

    The carglumic acid market is expected to witness an impressive growth of 7.7% CAGR in the coming years.

    Apothecon Pharmaceuticals Pvt Ltd (India), Manus Aktteva Biopharma LLP (India), Recordati Rare Diseases Inc (US), Dipharma Francis S r l (Italy), Civentichem LLC (US), Dipharma S A (Switzerland), NURAY CHEMICALS (India), NOVITIUM PHARMA LLC (US), Suven Life Sciences Limited (India), Biophore India Pharmaceuticals Pvt Ltd (India) are among the key players in the carglumic acid market.

    The carglumic acid market size is expected to reach USD 188.8 million in the foreseeable future.

    The hospital pharmacies segment held a substantial share in the carglumic acid market in 2020.

    North America accounted for the largest share in the carglumic acid market in 2020.

    Asia-pacific is expected to grow at a healthy CAGR in the carglumic acid market in the next five years.